Chilblain-Like Lesions During COVID-19 Tied to Type I Interferonopathy
TUESDAY, Dec. 1, 2020 -- Patients presenting with chilblain-like lesions during the COVID-19 pandemic have histologic and biologic patterns of type I interferonopathy, according to a study published online Nov. 25 in JAMA Dermatology.
Thomas Hubiche, M.D., from Université Côte d'Azur in Nice, France, and colleagues assessed 40 consecutive patients presenting with chilblain-like lesions during the COVID-19 pandemic. Patients underwent skin biopsies, vascular investigations, biologic analyses, interferon-alpha stimulation and detection, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction and serologic analysis.
The researchers found that most patients were young, with a median age of 22 years, and 19 patients were male. Chilblain-like lesions were mostly on the toes. Eleven patients had bullous and necrotic evolution, while 19 had acrocyanosis or cold toes. Just over one-fourth of patients (27.5 percent) had criteria compatible with COVID-19 cases within six weeks of the eruption, although all rapid testing results were negative. SARS-CoV-2 serology results were positive in 12 patients (30 percent). Six in 10 patients had elevated D-dimer concentration levels. All patients tested negative for cryoglobulinemia and parvovirus B19. Lymphocytic inflammation and vascular damage with thickening of venule walls and pericyte hyperplasia were the major histologic findings.
"Taken together, our results suggest that chilblain-like lesions observed during the COVID-19 pandemic represent manifestations of a viral-induced type I interferonopathy," the authors write.
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Further Support and Information on COVID-19
Read this next
WEDNESDAY, Jan. 27, 2021 -- Certain risk factors are associated with college students self-reporting a psychological impact of the COVID-19 pandemic, according to a study...
WEDNESDAY, Jan. 27, 2021 -- Retired doctors and nurses are being called to the front lines of the U.S. COVID-19 vaccination effort, the White House COVID-19 Response team...
WEDNESDAY, Jan. 27, 2021 -- For patients hospitalized with COVID-19, respiratory, physical, and psychological sequelae are common at four months after discharge, according to a...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.